Alzheimer's Disease Clinical Trial
Official title:
Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)
Verified date | May 2020 |
Source | University of Southern California |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
An urgent need exists to find effective treatments for Alzheimer's disease (AD) that can
arrest or reverse the disease at its earliest stages. The emotional and financial burden of
AD to patients, family members, and society is enormous, and is predicted to grow
exponentially as the median population age increases. Current FDA-approved therapies are
modestly effective at best. This study will examine a novel therapeutic approach using
intranasal insulin (INI) that has shown promise in short-term clinical trials. If successful,
information gained from the study has the potential to move INI forward rapidly as a therapy
for AD. The study will also provide evidence for the mechanisms through which INI may produce
benefits by examining key cerebral spinal fluid (CSF) biomarkers and hippocampal/entorhinal
atrophy. These results will have considerable clinical and scientific significance, and
provide therapeutically-relevant knowledge about insulin's effects on AD pathophysiology.
Growing evidence has shown that insulin carries out multiple functions in the brain, and that
insulin dysregulation may contribute to AD pathogenesis.
This study will examine the effects of intranasally-administered insulin on cognition,
entorhinal cortex and hippocampal atrophy, and cerebrospinal fluid (CSF) biomarkers in
amnestic mild cognitive impairment (aMCI) or mild AD. It is hypothesized that after 12 months
of treatment with INI compared to placebo, subjects will improve performance on a global
measure of cognition, on a memory composite and on daily function. In addition to the
examination of CSF biomarkers and hippocampal and entorhinal atrophy, the study aims to
examine whether baseline AD biomarker profile, gender, or Apolipoprotein epsilon 4 (APOE-ε4)
allele carriage predict treatment response.
In this study, 240 people with aMCI or AD will be given either INI or placebo for 12 months,
following an open-label period of 6 months where all participants will be given active drug.
The study uses insulin as a therapeutic agent and intranasal administration focusing on nose
to brain transport as a mode of delivery.
Status | Completed |
Enrollment | 240 |
Est. completion date | December 11, 2018 |
Est. primary completion date | December 11, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Fluent in English or Spanish - Diagnosis of aMCI by Petersen criteria or probable AD by National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria - Mini Mental State Examination (MMSE) score at screening is greater than or equal to 20 - Clinical Dementia Rating is 0.5-1 at screening - Logical Memory is less than or equal to 8 for 16 or more years of education, less than or equal to 4 for 8-15 years of education, less than or equal to 2 for 0-7 years of education. Scores measured at screening on Delayed Paragraph Recall (Paragraph A only) from the Wechsler Memory Scale-Revised - Able to complete baseline assessments - Modified Hachinski score of less than or equal to 4 - A study partner able to accompany the participant to most visits and answer questions about the participant - The study partner must have direct contact with the participant more than 2 days per week (minimum of 10 hours per week) and provide supervision of drug administration as needed - Stable medical condition for 3 months prior to screening visit - Stable medications for 4 weeks prior to the screening and baseline visits - Stable use of permitted medications - At least six years of education or work history - Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the investigator - Visual and auditory acuity adequate for neuropsychological testing Exclusion Criteria: - A diagnosis of dementia other than probable AD - Probable AD with Down syndrome - History of clinically significant stroke - Current evidence or history in past two years of epilepsy, focal brain lesion, head injury with loss of consciousness or Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV) criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse - Sensory impairment that would preclude the participant from participating in or cooperating with the protocol - Diabetes (type 1 or type II) requiring pharmacologic treatment (including both insulin dependent and non-insulin dependent diabetes mellitus) - Current or past use of insulin or any other anti-diabetic medication - Evidence of any significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving investigational drug including clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, endocrine, metabolic, renal or other systemic disease or laboratory abnormality. - Active neoplastic disease, history of cancer five years prior to screening (history of skin melanoma or stable prostate cancer are not excluded) - History of seizure within the past five years - Pregnancy or possible pregnancy - Contraindications to Lumbar Puncture (LP) procedure: prior lumbosacral spine surgery, severe degenerative joint disease or deformity of the spine, platelets is less than 100,000 or history of bleeding disorder - Use of anticoagulants warfarin (Coumadin) and dabigatran (Pradaxa) due to LP requirement - Contraindications for MRI (claustrophobia, craniofacial metal implants of any kind, pacemakers) - Residence in a skilled nursing facility at screening - Use of an investigational agent within two months or screening visit - Regular use of narcotics, anticonvulsants, medications with significant anticholinergic activity, antiparkinsonian medications or any other exclusionary medications |
Country | Name | City | State |
---|---|---|---|
United States | Emory University | Atlanta | Georgia |
United States | Johns Hopkins University | Baltimore | Maryland |
United States | Case Western Reserve University | Beachwood | Ohio |
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | Roper St. Francis Hospital | Charleston | South Carolina |
United States | Northwestern University | Chicago | Illinois |
United States | Rush University Medical Center | Chicago | Illinois |
United States | Baylor College of Medicine | Houston | Texas |
United States | Indiana University | Indianapolis | Indiana |
United States | University of California, Irvine | Irvine | California |
United States | Mayo Clinic, Jacksonville | Jacksonville | Florida |
United States | University of Kentucky | Lexington | Kentucky |
United States | Yale University School of Medicine | New Haven | Connecticut |
United States | Mount Sinai School of Medicine | New York | New York |
United States | Banner Alzheimer's Institute | Phoenix | Arizona |
United States | Barrow Neurology Clinics | Phoenix | Arizona |
United States | Rhode Island Hospital | Providence | Rhode Island |
United States | Mayo Clinic, Rochester | Rochester | Minnesota |
United States | University of Rochester Medical Center | Rochester | New York |
United States | U of WA / VA Puget Sound Alzheimer's Disease Research Center | Seattle | Washington |
United States | Tulsa Clinical Research | Tulsa | Oklahoma |
United States | Georgetown University | Washington | District of Columbia |
United States | Howard University | Washington | District of Columbia |
United States | Wake Forest University Health Sciences | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
University of Southern California | Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA), Wake Forest University Health Sciences |
United States,
Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011 Jan;68(1):51-7. doi: 10.1001/archneurol.2010.225. Epub 2010 Sep 13. — View Citation
Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012 Jan;69(1):29-38. doi: 10.1001/archneurol.2011.233. Epub 2011 Sep 12. — View Citation
Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998 Jan;50(1):164-8. — View Citation
Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008 Feb 5;70(6):440-8. Epub 2007 Oct 17. Erratum in: Neurology. 2008 Sep 9;71(11):866. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Global Measure of Cognition as Measured by the Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12) | The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. The ADAS-Cog12 version was used in this study which includes Delayed Word Recall - a measure of episodic memory. Scores from the original portion of the test range from 0 (best) to 70 (worse) and then number of items not recalled ranging from 0-10 is added for a maximum score of 80. A positive change indicates cognitive worsening. | 12 months (blinded phase) followed by 6 months (open label phase) | |
Secondary | Change in Memory Composite as Measured by Story Recall (Immediate Paragraph Recall and Delayed Paragraph Recall) and Free and Cued Selective Reminding Test (FCSRT) | Memory Composite is composed from Story Recall (both Immediate Paragraph Recall and Delayed Paragraph Recall) and the Free and Cued Selective Reminding Test (FCSRT). Each of the three component scores were normalized by subtracting the baseline sample mean, and dividing by the baseline sample standard deviation, to form three separately standardized z-scores with mean 0 and standard deviation 1. The three Z-scores were summed to form the memory composite. No other standardization was performed on the sum. If any of Immediate Paragraph Recall, Delayed Paragraph Recall and FCSRT is missing, the memory composite is missing. Higher scores indicate better performance. In this study the scores ranged from about -4.74 to 9.15 at baseline, and about -5.10 to 9.43 across all visits over 12 months. | 12 months (blinded phase) followed by 6 months (open label phase) | |
Secondary | Change in Daily Functioning as Measured by the ADCS-MCI Activities of Daily Living (ADCS-ADL-MCI) | The Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale (ADCS-ADL) is an activities of daily living questionnaire aimed at detecting functional decline in people with Mild Cognitive Impairment (MCI). In a structured interview format, informants are queried as to whether participants attempted each item in the inventory during the prior 4 weeks and their level of performance. The questions focus predominantly on instrumental activities of daily living scales (e.g. shopping, preparing meals, using household appliances, keeping appointments, reading). The total score can range from 0-54. A higher score indicates greater functional ability. | 12 months (blinded phase) and 6 months (open label phase) | |
Secondary | Change in Cognitive Deficit as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB) | The Clinical Dementia Rating - Sum of Boxes (CDR-SB) is administered as a structured interview with the participant and study partner, where impairment is scored in each of categories: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. Impairment is scored on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2 and severe = 3. The 6 individual category ratings, or "box scores", are added together to give the CDR-Sum of Boxes which ranges from 0-18 with higher scores indicated more impairment. | 12 months (blinded phase) followed by 6 months (open label phase) | |
Secondary | Change in Hippocampal and Entorhinal Atrophy as Measured by Magnetic Resonance Imaging (MRI) | MRI will be used to assess the effect of treatment on rate of hippocampal and entorhinal atrophy, and conduct exploratory analyses of other brain regions. Volume change was normalized to the participant's own intracranial volume to account for each participant's brain size. | Screen and Month 12 | |
Secondary | Change in CSF Biomarkers of AD | Quantify Abeta and Tau biomarkers in CSF | Baseline and Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02309723 -
How Beta-amyloid Imagining Influences Clinician Diagnosis and Management of Hypothetical Patients With Cognitive Complaints
|
N/A |